LT2989088T - Dolastatino 10 ir auristatinų dariniai - Google Patents

Dolastatino 10 ir auristatinų dariniai

Info

Publication number: LT2989088T
Authority: LT; Lithuania
Prior art keywords: auristatines; dolastatin
Prior art date: 2013-04-25

Application number

LTEP14720946.4T

Other languages

English (en)

Inventor

Michel Perez

Ian RILATT

Marie Lamothe

Original Assignee

Pierre Fabre Médicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-25

Filing date

2014-04-25

Publication date

2018-01-10

2014-04-25 Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament

2018-01-10 Publication of LT2989088T publication Critical patent/LT2989088T/lt

Links

OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 title 1
OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 title 1
108010045524 dolastatin 10 Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Crystallography & Structural Chemistry (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LTEP14720946.4T 2013-04-25 2014-04-25 Dolastatino 10 ir auristatinų dariniai LT2989088T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR1353793A FR3005051A1 (fr)	2013-04-25	2013-04-25	Derives de la dolastatine 10 et d'auristatines
PCT/EP2014/058427 WO2014174064A1 (en)	2013-04-25	2014-04-25	Derivatives of dolastatin 10 and auristatins

Publications (1)

Publication Number	Publication Date
LT2989088T true LT2989088T (lt)	2018-01-10

Family

ID=48782433

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP14719328.8T LT2989086T (lt)	2013-04-25	2014-04-25	Dolastino 10 ir auristatinų dariniai
LTEP14720946.4T LT2989088T (lt)	2013-04-25	2014-04-25	Dolastatino 10 ir auristatinų dariniai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP14719328.8T LT2989086T (lt)	2013-04-25	2014-04-25	Dolastino 10 ir auristatinų dariniai

Country Status (32)

Country	Link
US (7)	US20160068566A1 (lt)
EP (4)	EP2989086B1 (lt)
JP (3)	JP6017728B2 (lt)
KR (4)	KR102368136B1 (lt)
CN (3)	CN105143199A (lt)
AU (3)	AU2014259431B2 (lt)
BR (3)	BR112015026565A2 (lt)
CA (4)	CA2910176C (lt)
CY (2)	CY1119677T1 (lt)
DK (3)	DK2989086T3 (lt)
ES (3)	ES2654364T3 (lt)
FR (1)	FR3005051A1 (lt)
HK (1)	HK1215580A1 (lt)
HR (2)	HRP20181890T1 (lt)
HU (3)	HUE035180T2 (lt)
IL (1)	IL242184A (lt)
LT (2)	LT2989086T (lt)
MA (1)	MA38583B1 (lt)
MX (3)	MX2015014831A (lt)
MY (1)	MY177702A (lt)
NO (1)	NO2989088T3 (lt)
NZ (1)	NZ714203A (lt)
PL (3)	PL2989088T3 (lt)
PT (2)	PT2989086T (lt)
RS (2)	RS56717B1 (lt)
RU (3)	RU2015147447A (lt)
SA (1)	SA515370043B1 (lt)
SI (2)	SI2989088T1 (lt)
TN (2)	TN2015000445A1 (lt)
UA (1)	UA115806C2 (lt)
WO (3)	WO2014174062A1 (lt)
ZA (1)	ZA201508545B (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR3005051A1 (fr) *	2013-04-25	2014-10-31	Pf Medicament	Derives de la dolastatine 10 et d'auristatines
MX378281B (es) *	2014-04-25	2025-03-10	Pf Medicament	Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
MA39909B1 (fr)	2014-04-25	2019-05-31	Pf Medicament	Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
US10973920B2 (en)	2014-06-30	2021-04-13	Glykos Finland Oy	Saccharide derivative of a toxic payload and antibody conjugates thereof
US11384104B2 (en)	2015-06-19	2022-07-12	Centurion Biopharma Corporation	Delivery systems for controlled drug release
JP2019510000A (ja) *	2016-02-26	2019-04-11	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	新規トキシン及びその中間体の製造方法
ES2948846T3 (es) *	2016-03-29	2023-09-20	Toray Industries	Derivado peptídico y uso del mismo
CN105968038A (zh) *	2016-05-09	2016-09-28	湖北华世通生物医药科技有限公司	二肽类化合物的盐酸盐及其制备方法
CN106432318A (zh) *	2016-08-18	2017-02-22	重庆大学	一种芳炔前体的设计，合成，及在合成多取代芳烃的应用
CN107325033A (zh) *	2017-06-23	2017-11-07	华东师范大学	一种高立体选择性合成海兔毒素Dap片段的方法
BR112020009836A2 (pt) *	2017-11-30	2020-10-13	Centurion Biopharma Corporation	pró-drogas de ligação a albumina de derivados de auristatina e
CN113453724B (zh)	2018-09-27	2025-02-25	皮埃尔法布雷医药公司	基于磺酰基马来酰亚胺的连接子和相应的偶联物
CN110724337B (zh) *	2019-10-16	2022-04-05	江苏德威新材料股份有限公司	一种硅烷交联型阻燃半导电聚烯烃护套材料及其制备方法和应用
CA3230737A1 (en)	2021-09-03	2023-03-09	Toray Industries, Inc.	Pharmaceutical composition for cancer treatment and/or prevention
KR20250143351A (ko)	2023-04-12	2025-10-01	레메젠 코, 리미티드	모노메틸 아우리스타틴 e 화합물의 제조 및 정제 방법
WO2024230625A1 (zh) *	2023-05-06	2024-11-14	荣昌生物制药(烟台)股份有限公司	一种奥瑞他汀衍生物中间体的制备方法
CN121241045A (zh) *	2023-06-02	2025-12-30	荣昌生物制药(烟台)股份有限公司	一种甲基奥瑞他汀e化合物中间体的制备及纯化方法
CN118165066B (zh) *	2024-02-26	2025-03-21	复旦大学	一种含氟多肽及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0731106B1 (en) *	1993-10-01	2004-11-17	Teikoku Hormone Mfg. Co., Ltd.	Dolastatin derivatives
US6884869B2 (en) *	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
ES2708763T3 (es) *	2005-07-07	2019-04-11	Seattle Genetics Inc	Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
ES2588194T3 (es) *	2008-04-11	2016-10-31	Seattle Genetics, Inc.	Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
WO2010111018A1 (en) *	2009-03-06	2010-09-30	Agensys, Inc.	Antibody drug conjugates (adc) that bind to 24p4c12 proteins
CN103200950B (zh) *	2010-06-10	2016-03-16	西雅图基因公司	新颖的耳他汀衍生物及其用途
US8987209B2 (en) *	2010-09-29	2015-03-24	Seattle Genetics, Inc.	N-carboxyalkyl-auristatin and the use thereof
CA2813411C (en) *	2010-11-05	2016-08-02	Rinat Neuroscience Corporation	Engineered polypeptide conjugates and methods for making thereof using transglutaminase
ES2543888T3 (es) *	2011-03-16	2015-08-25	Seattle Genetics, Inc.	N-carboxialquil-auristatinas y su utilización
SG194567A1 (en) *	2011-04-21	2013-12-30	Seattle Genetics Inc	Novel binder-drug conjugates (adcs) and their use
DK2714685T3 (en) *	2011-05-27	2017-01-09	Ambrx Inc	FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
KR20200128601A (ko) *	2011-05-27	2020-11-13	암브룩스, 인코포레이티드	비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
EP3536700A1 (en) *	2012-06-07	2019-09-11	Ambrx, Inc.	Prostate-specific membrane antigen antibody drug conjugates
CN111499684B (zh) *	2012-06-19	2024-10-22	Ambrx公司	抗cd70抗体药物结合物
US20150314007A1 (en) *	2012-12-21	2015-11-05	Glykos Finland Oy	Linker-payload molecule conjugates
FR3005051A1 (fr) *	2013-04-25	2014-10-31	Pf Medicament	Derives de la dolastatine 10 et d'auristatines
MX378281B (es) *	2014-04-25	2025-03-10	Pf Medicament	Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.

2013
- 2013-04-25 FR FR1353793A patent/FR3005051A1/fr not_active Withdrawn
2014
- 2014-04-25 EP EP14719328.8A patent/EP2989086B1/en active Active
- 2014-04-25 LT LTEP14719328.8T patent/LT2989086T/lt unknown
- 2014-04-25 ES ES14720946.4T patent/ES2654364T3/es active Active
- 2014-04-25 EP EP18172389.1A patent/EP3388427B1/en not_active Not-in-force
- 2014-04-25 DK DK14719328.8T patent/DK2989086T3/en active
- 2014-04-25 RS RS20171344A patent/RS56717B1/sr unknown
- 2014-04-25 PL PL14720946T patent/PL2989088T3/pl unknown
- 2014-04-25 NZ NZ714203A patent/NZ714203A/en not_active IP Right Cessation
- 2014-04-25 DK DK18172389.1T patent/DK3388427T3/da active
- 2014-04-25 RU RU2015147447A patent/RU2015147447A/ru unknown
- 2014-04-25 HU HUE14720946A patent/HUE035180T2/hu unknown
- 2014-04-25 TN TN2015000445A patent/TN2015000445A1/en unknown
- 2014-04-25 AU AU2014259431A patent/AU2014259431B2/en not_active Ceased
- 2014-04-25 CA CA2910176A patent/CA2910176C/en active Active
- 2014-04-25 RS RS20181410A patent/RS58161B1/sr unknown
- 2014-04-25 CA CA2909126A patent/CA2909126A1/en not_active Abandoned
- 2014-04-25 SI SI201430523T patent/SI2989088T1/en unknown
- 2014-04-25 CA CA3130994A patent/CA3130994A1/en active Pending
- 2014-04-25 WO PCT/EP2014/058425 patent/WO2014174062A1/en not_active Ceased
- 2014-04-25 HU HUE14719328A patent/HUE040431T2/hu unknown
- 2014-04-25 ES ES14719328.8T patent/ES2693368T3/es active Active
- 2014-04-25 HR HRP20181890TT patent/HRP20181890T1/hr unknown
- 2014-04-25 UA UAA201511563A patent/UA115806C2/uk unknown
- 2014-04-25 MX MX2015014831A patent/MX2015014831A/es unknown
- 2014-04-25 MA MA38583A patent/MA38583B1/fr unknown
- 2014-04-25 JP JP2016509483A patent/JP6017728B2/ja active Active
- 2014-04-25 JP JP2016509480A patent/JP6606489B2/ja not_active Expired - Fee Related
- 2014-04-25 US US14/783,003 patent/US20160068566A1/en not_active Abandoned
- 2014-04-25 HK HK16103554.4A patent/HK1215580A1/zh unknown
- 2014-04-25 BR BR112015026565A patent/BR112015026565A2/pt not_active IP Right Cessation
- 2014-04-25 HR HRP20171977TT patent/HRP20171977T1/hr unknown
- 2014-04-25 SI SI201430953T patent/SI2989086T1/sl unknown
- 2014-04-25 KR KR1020157033192A patent/KR102368136B1/ko not_active Expired - Fee Related
- 2014-04-25 PT PT14719328T patent/PT2989086T/pt unknown
- 2014-04-25 HU HUE18172389A patent/HUE058167T2/hu unknown
- 2014-04-25 WO PCT/EP2014/058422 patent/WO2014174060A1/en not_active Ceased
- 2014-04-25 US US14/786,921 patent/US20160083420A1/en not_active Abandoned
- 2014-04-25 PL PL18172389T patent/PL3388427T3/pl unknown
- 2014-04-25 ES ES18172389T patent/ES2908224T3/es active Active
- 2014-04-25 MX MX2015014746A patent/MX372911B/es active IP Right Grant
- 2014-04-25 MX MX2015014941A patent/MX345126B/es active IP Right Grant
- 2014-04-25 EP EP14719330.4A patent/EP2989087A1/en not_active Withdrawn
- 2014-04-25 RU RU2015146957A patent/RU2015146957A/ru unknown
- 2014-04-25 AU AU2014259429A patent/AU2014259429A1/en not_active Abandoned
- 2014-04-25 PL PL14719328T patent/PL2989086T3/pl unknown
- 2014-04-25 BR BR112015026410-7A patent/BR112015026410B1/pt not_active IP Right Cessation
- 2014-04-25 US US14/784,163 patent/US20160068567A1/en not_active Abandoned
- 2014-04-25 KR KR1020157033193A patent/KR20160003735A/ko not_active Withdrawn
- 2014-04-25 EP EP14720946.4A patent/EP2989088B1/en active Active
- 2014-04-25 MY MYPI2015703517A patent/MY177702A/en unknown
- 2014-04-25 AU AU2014259427A patent/AU2014259427B2/en not_active Ceased
- 2014-04-25 LT LTEP14720946.4T patent/LT2989088T/lt unknown
- 2014-04-25 PT PT147209464T patent/PT2989088T/pt unknown
- 2014-04-25 CN CN201480023286.3A patent/CN105143199A/zh active Pending
- 2014-04-25 WO PCT/EP2014/058427 patent/WO2014174064A1/en not_active Ceased
- 2014-04-25 KR KR1020217012000A patent/KR102389167B1/ko not_active Expired - Fee Related
- 2014-04-25 BR BR112015026478A patent/BR112015026478A2/pt not_active Application Discontinuation
- 2014-04-25 DK DK14720946.4T patent/DK2989088T3/en active
- 2014-04-25 KR KR1020157033194A patent/KR101640361B1/ko active Active
- 2014-04-25 RU RU2015149527A patent/RU2662951C2/ru active
- 2014-04-25 JP JP2016509482A patent/JP2016519114A/ja active Pending
- 2014-04-25 CN CN201480032708.3A patent/CN105408318A/zh active Pending
- 2014-04-25 CN CN201480030093.0A patent/CN105377834B/zh active Active
- 2014-04-25 NO NO14720946A patent/NO2989088T3/no unknown
- 2014-04-25 CA CA2910178A patent/CA2910178A1/en not_active Abandoned
2015
- 2015-09-28 TN TN2015000439A patent/TN2015000439A1/en unknown
- 2015-10-20 IL IL242184A patent/IL242184A/en active IP Right Grant
- 2015-10-22 SA SA515370043A patent/SA515370043B1/ar unknown
- 2015-11-19 ZA ZA2015/08545A patent/ZA201508545B/en unknown
2017
- 2017-09-19 US US15/708,685 patent/US20180222858A1/en not_active Abandoned
- 2017-12-15 CY CY20171101313T patent/CY1119677T1/el unknown
2018
- 2018-11-15 CY CY181101213T patent/CY1120863T1/el unknown
2019
- 2019-05-30 US US16/426,532 patent/US20200010414A1/en not_active Abandoned
2020
- 2020-10-27 US US17/081,162 patent/US20210107868A1/en not_active Abandoned
2022
- 2022-08-11 US US17/819,089 patent/US20230002316A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2014174062A1 (en)	2014-10-30
HK1215867A1 (zh)	2016-09-23
BR112015026478A2 (pt)	2017-07-25
PL3388427T3 (pl)	2022-05-09
CA2910178A1 (en)	2014-10-30
AU2014259431A1 (en)	2015-12-03
CN105143199A (zh)	2015-12-09
MX345126B (es)	2017-01-17
ES2654364T3 (es)	2018-02-13
AU2014259427A1 (en)	2015-11-19
AU2014259431B2 (en)	2017-02-02
EP3388427A1 (en)	2018-10-17
US20230002316A1 (en)	2023-01-05
MA38583A1 (fr)	2018-07-31
EP2989086B1 (en)	2018-08-22
ZA201508545B (en)	2017-07-26
TN2015000439A1 (en)	2017-01-03
DK3388427T3 (da)	2022-03-07
UA115806C2 (uk)	2017-12-26
US20210107868A1 (en)	2021-04-15
CN105377834A (zh)	2016-03-02
JP2016520041A (ja)	2016-07-11
AU2014259427B2 (en)	2018-04-05
NO2989088T3 (lt)	2018-02-24
MY177702A (en)	2020-09-23
HUE058167T2 (hu)	2022-07-28
LT2989086T (lt)	2018-11-26
DK2989088T3 (en)	2017-12-18
HK1215580A1 (zh)	2016-09-02
HRP20171977T1 (hr)	2018-02-09
PT2989088T (pt)	2018-01-03
ES2908224T3 (es)	2022-04-28
CA2910176C (en)	2021-11-09
HUE035180T2 (hu)	2018-05-02
RU2015147447A (ru)	2017-05-31
BR112015026410A2 (pt)	2017-07-25
MX372911B (es)	2020-04-27
KR20210046871A (ko)	2021-04-28
KR20160003735A (ko)	2016-01-11
RS58161B1 (sr)	2019-03-29
WO2014174060A1 (en)	2014-10-30
SI2989088T1 (en)	2018-02-28
RU2662951C2 (ru)	2018-07-31
MX2015014746A (es)	2016-03-04
CA3130994A1 (en)	2014-10-30
DK2989086T3 (en)	2018-11-12
KR102389167B1 (ko)	2022-04-20
PL2989086T3 (pl)	2019-02-28
JP6017728B2 (ja)	2016-11-02
CY1120863T1 (el)	2019-12-11
US20160068567A1 (en)	2016-03-10
US20200010414A1 (en)	2020-01-09
CN105377834B (zh)	2018-04-20
EP2989088A1 (en)	2016-03-02
US20160083420A1 (en)	2016-03-24
SA515370043B1 (ar)	2018-01-24
MX2015014941A (es)	2016-03-07
FR3005051A1 (fr)	2014-10-31
PL2989088T3 (pl)	2018-03-30
CY1119677T1 (el)	2018-04-04
EP3388427B1 (en)	2022-01-19
WO2014174064A1 (en)	2014-10-30
KR102368136B1 (ko)	2022-02-25
CN105408318A (zh)	2016-03-16
JP6606489B2 (ja)	2019-11-13
JP2016519114A (ja)	2016-06-30
PT2989086T (pt)	2018-11-29
EP2989086A1 (en)	2016-03-02
HRP20181890T1 (hr)	2019-01-11
KR20160003734A (ko)	2016-01-11
MX2015014831A (es)	2016-08-03
BR112015026565A2 (pt)	2017-07-25
RU2015146957A (ru)	2017-05-31
EP2989088B1 (en)	2017-09-27
TN2015000445A1 (en)	2017-04-06
SI2989086T1 (sl)	2018-12-31
CA2910176A1 (en)	2014-10-30
IL242184A (en)	2017-09-28
EP2989087A1 (en)	2016-03-02
ES2693368T3 (es)	2018-12-11
AU2014259429A1 (en)	2015-11-12
KR101640361B1 (ko)	2016-07-15
RU2015149527A (ru)	2017-05-29
CA2909126A1 (en)	2014-10-30
US20180222858A1 (en)	2018-08-09
RS56717B1 (sr)	2018-03-30
US20160068566A1 (en)	2016-03-10
NZ714203A (en)	2020-05-29
KR20160003003A (ko)	2016-01-08
JP2016519115A (ja)	2016-06-30
HUE040431T2 (hu)	2019-03-28
MA38583B1 (fr)	2018-11-30
BR112015026410B1 (pt)	2022-06-07

Publication	Publication Date	Title
IL276106A (en)	2020-08-31	Garp-binding proteins and their uses
LT3368534T (lt)	2021-04-12	Valbenazino ditozilatas ir jo polimorfai
LT2970303T (lt)	2017-07-25	Pakeistieji ksantinai ir jų panaudojimo metodai
LT3003039T (lt)	2021-05-10	Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
LT2976117T (lt)	2021-02-25	Purkštuvas ir surinkimo būdas
LT3317284T (lt)	2020-01-27	Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
LT3280441T (lt)	2021-11-25	Anti-sortilino antikūnai ir jų naudojimo būdai
LT3019483T (lt)	2020-03-10	Terapiniu požiūriu aktyvūs junginiai ir jų panaudojimo būdai
LT3215532T (lt)	2020-01-10	Anti-tim3 antikūnai ir jų naudojimo būdai
LT3333191T (lt)	2020-12-10	Anti-c10orf54 antikūnai ir jų panaudojimas
LT3394065T (lt)	2021-06-25	Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
IL245036B (en)	2020-10-29	Pesticidal compositions and related methods
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3319612T (lt)	2021-08-25	Oksisteroliai ir jų naudojimo būdai
LT3102555T (lt)	2021-06-25	Junginių kompozicijos ir jų panaudojimas
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
HRP20181890T1 (hr)	2019-01-11	Derivati dolastatina 10 i auristatina
LT3030519T (lt)	2022-04-11	Tricikliniai benzoksaborolo junginiai ir jų naudojimas
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf
SI3672948T1 (sl)	2023-01-31	Piridinamin-piridon in spojine pirimidinamin-piridona
DK3052522T3 (da)	2020-02-24	Anti-sox 10 antistofsystemer og -fremgangsmåder
LT2948559T (lt)	2018-06-25	Kv1.3 antagonistai ir jų panaudojimo būdai
PL3331063T3 (pl)	2021-11-02	Akumulator i zespół akumulatorowy